




*vaccines*



an Open Access Journal by MDPI

## Safety and Side Effects in SARS-CoV-2 Vaccine

Guest Editors:

### **Dr. Ying-Fei Yang**

Department of Bioenvironmental  
Systems Engineering, National  
Taiwan University, Taipei 10617,  
Taiwan

### **Dr. Sher Singh**

Department of Life Science,  
School of Life Science, College of  
Science, National Taiwan Normal  
University, Taipei 11677, Taiwan

Deadline for manuscript  
submissions:

**28 February 2026**

### **Message from the Guest Editors**

COVID-19 vaccines are important in the global battle against the SARS-CoV-2 pandemic. The swift development and distribution of COVID-19 vaccines, including mRNA (Pfizer-BioNTech, Moderna), viral vector (AstraZeneca, Johnson & Johnson, Sputnik V), and protein subunit (Novavax) vaccines, or inactivated virus (Sinovac, Sinopharm) vaccines, have been unprecedented. This Special Issue invites research papers and reviews that enhance current understanding of these vaccines' safety and side effects, focusing on special populations (e.g., the elderly and children, pregnant and lactating women, and immunocompromised individuals) and rare adverse events. Understanding these aspects is critical for healthcare providers and policymakers to improve vaccine confidence and optimize public health strategies. We also welcome articles on vaccine safety monitoring systems, e.g., the vaccine adverse event reporting system (VAERS) and the vaccine safety datalink (VSD). We look forward to receiving your research articles, including reviews.



[mdpi.com/si/207374](https://mdpi.com/si/207374)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)